Several studies have shown how systemic inflammatory markers [C-reactive protein (CRP) and neutrophil–lymphocyte ratio (NLR)] may indicate a poor prognosis in many cancers (esophageal, stomach, colon, liver, renal, prostatic, ovarian, skin and pancreatic cancer) [4,5]. This evidence concerns the gene CRP and pancreatic neoplasm.